1. Home
  2. CRSP vs COMP Comparison

CRSP vs COMP Comparison

Compare CRSP & COMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CRSP
  • COMP
  • Stock Information
  • Founded
  • CRSP 2013
  • COMP 2012
  • Country
  • CRSP Switzerland
  • COMP United States
  • Employees
  • CRSP N/A
  • COMP N/A
  • Industry
  • CRSP Biotechnology: Biological Products (No Diagnostic Substances)
  • COMP EDP Services
  • Sector
  • CRSP Health Care
  • COMP Technology
  • Exchange
  • CRSP Nasdaq
  • COMP Nasdaq
  • Market Cap
  • CRSP 4.9B
  • COMP 4.9B
  • IPO Year
  • CRSP 2016
  • COMP 2021
  • Fundamental
  • Price
  • CRSP $59.62
  • COMP $9.75
  • Analyst Decision
  • CRSP Buy
  • COMP Buy
  • Analyst Count
  • CRSP 16
  • COMP 8
  • Target Price
  • CRSP $72.27
  • COMP $9.75
  • AVG Volume (30 Days)
  • CRSP 1.8M
  • COMP 7.2M
  • Earning Date
  • CRSP 11-04-2025
  • COMP 10-29-2025
  • Dividend Yield
  • CRSP N/A
  • COMP N/A
  • EPS Growth
  • CRSP N/A
  • COMP N/A
  • EPS
  • CRSP N/A
  • COMP N/A
  • Revenue
  • CRSP $38,050,000.00
  • COMP $6,290,200,000.00
  • Revenue This Year
  • CRSP N/A
  • COMP $24.34
  • Revenue Next Year
  • CRSP $348.18
  • COMP $12.93
  • P/E Ratio
  • CRSP N/A
  • COMP N/A
  • Revenue Growth
  • CRSP N/A
  • COMP 21.23
  • 52 Week Low
  • CRSP $30.04
  • COMP $5.10
  • 52 Week High
  • CRSP $71.13
  • COMP $10.25
  • Technical
  • Relative Strength Index (RSI)
  • CRSP 60.26
  • COMP 65.83
  • Support Level
  • CRSP $51.63
  • COMP $9.15
  • Resistance Level
  • CRSP $62.08
  • COMP $9.60
  • Average True Range (ATR)
  • CRSP 2.52
  • COMP 0.36
  • MACD
  • CRSP 0.84
  • COMP -0.04
  • Stochastic Oscillator
  • CRSP 78.13
  • COMP 84.26

About CRSP CRISPR Therapeutics AG

Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.

About COMP Compass Inc.

Compass Inc provides an end-to-end platform that empowers residential real estate agents to deliver exceptional service to seller and buyer clients. The platform includes an integrated suite of cloud-based software for customer relationship management, marketing, client service and other critical functionality, all custom-built for the real estate industry and enabling core brokerage services. Business operations are conducted in the United States and earn revenue domestically.

Share on Social Networks: